Table 4. Additional treatments in advanced HCC patients with PD after sorafenib (n =141).
Additional treatment | n (%) |
---|---|
Sorafenib monotherapy | 58 (41) |
TACE | 24 (17) |
HAIC | 21(15) |
Systemic chemotherapy except for sorafenib | 18 (13) |
Radiation therapy | 18 (13) |
Hepatic resection | 3 (2) |
No treatment | 13 (9) |
HCC = Hepatocellular carcinoma; PD = progressive disease; TACE = transcatheter arterial chemoembolization; HAIC = hepatic arterial infusion chemotherapy